Genomic prostate score and treatment selection in favourable intermediate‐risk prostate cancer
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | Eric Margolis, Benjamin H. Lowentritt, Christopher M. Pieczonka, John P. Bennett, Marina Pavlova, Joao Paulo Zambon, Jack Groskopf, Edward Uchio |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer
by: Nicole Handa, et al.
Published: (2025)
by: Nicole Handa, et al.
Published: (2025)
First validation of the Prostatype® P‐score in an Asian cohort: Improving risk stratification for prostate cancer
by: See‐Tong Pang, et al.
Published: (2025)
by: See‐Tong Pang, et al.
Published: (2025)
Oncological outcomes post focal low‐dose‐rate brachytherapy in low‐intermediate risk prostate cancer
by: Mohammadmehdi Adhami, et al.
Published: (2026)
by: Mohammadmehdi Adhami, et al.
Published: (2026)
Variation in harms and benefits of prostate‐specific antigen screening for prostate cancer by socio‐clinical risk factors: A rapid review
by: Abel Tesfai, et al.
Published: (2024)
by: Abel Tesfai, et al.
Published: (2024)
Comparing outcomes of Aquablation versus holmium laser enucleation of prostate in the treatment of benign prostatic hyperplasia: A network meta‐analysis
by: Ansh Bhatia, et al.
Published: (2024)
by: Ansh Bhatia, et al.
Published: (2024)
Utility of dynamic contrast enhancement for clinically significant prostate cancer detection
by: Eric V. Li, et al.
Published: (2024)
by: Eric V. Li, et al.
Published: (2024)
Impact of multiparametric MRI and prostate biopsies on anxiety and quality of life in men with suspected prostate cancer
by: Esther H. J. Hamoen, et al.
Published: (2025)
by: Esther H. J. Hamoen, et al.
Published: (2025)
Extracapsular extension risk assessment using an artificial intelligence prostate cancer mapping algorithm
by: Alan Priester, et al.
Published: (2024)
by: Alan Priester, et al.
Published: (2024)
Influences on androgen deprivation therapy prescribing before surgery in high‐risk prostate cancer
by: Jennifer Dunsmore, et al.
Published: (2024)
by: Jennifer Dunsmore, et al.
Published: (2024)
Potential gains from radical treatment of men with prostate cancer according to life expectancy
by: Sandra Irenaeus, et al.
Published: (2025)
by: Sandra Irenaeus, et al.
Published: (2025)
Emerging tools for the early detection of prostate cancer
by: Muhammad Haider, et al.
Published: (2025)
by: Muhammad Haider, et al.
Published: (2025)
Quality of English‐ and Spanish‐language online content about prostate cancer genetics: Insights into potential contributors to prostate cancer disparities
by: Sophia M. Abusamra, et al.
Published: (2025)
by: Sophia M. Abusamra, et al.
Published: (2025)
Perioperative antibiotic prophylaxis, prostate size and transperineal prostate biopsy
by: Maxwell Louis Sandberg, et al.
Published: (2026)
by: Maxwell Louis Sandberg, et al.
Published: (2026)
Bibliometric analysis of focal therapy in prostate cancer research
by: Mohammed Shahait, et al.
Published: (2024)
by: Mohammed Shahait, et al.
Published: (2024)
Micro‐ultrasound tissue echogenicity predicts prostate cancer grade
by: Ailene E. Corona, et al.
Published: (2026)
by: Ailene E. Corona, et al.
Published: (2026)
Omission of contralateral biopsies in unilateral MRI‐suspicious prostate cancer has minimal impact on clinical risk assessment
by: Stijn M. van den Bosch, et al.
Published: (2026)
by: Stijn M. van den Bosch, et al.
Published: (2026)
Quantification of perineural invasion on prostate biopsy improves risk stratification in biopsy Grade Group 2–3 cancer
by: Yuki Teramoto, et al.
Published: (2026)
by: Yuki Teramoto, et al.
Published: (2026)
National survey of urologists' views on prostate cancer screening in the United Kingdom
by: Nikhil Mayor, et al.
Published: (2026)
by: Nikhil Mayor, et al.
Published: (2026)
Focal therapy in prostate cancer: Development, application and outcomes in the United Kingdom
by: Nadia Rokan, et al.
Published: (2025)
by: Nadia Rokan, et al.
Published: (2025)
Investigating the prognostic utility of GSTP1 promoter methylation in prostate cancer
by: Ruth Pidsley, et al.
Published: (2024)
by: Ruth Pidsley, et al.
Published: (2024)
Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer
by: Arjun Pon Avudaiappan, et al.
Published: (2024)
by: Arjun Pon Avudaiappan, et al.
Published: (2024)
Increased risk of bleeding during and after HoLEP in patients with prostate cancer: A multicentre comparative cohort study
by: Angelo Porreca, et al.
Published: (2025)
by: Angelo Porreca, et al.
Published: (2025)
Racial and socioeconomic disparities in surgical care for post‐prostate cancer treatment complications: A nationwide Medicare‐based analysis
by: Oluwafolajimi Adesanya, et al.
Published: (2024)
by: Oluwafolajimi Adesanya, et al.
Published: (2024)
‘It Just Makes Sense to Me’: A qualitative study exploring patient decision‐making and experiences with prostate MRI during active surveillance for prostate cancer
by: Ryan Sutherland, et al.
Published: (2024)
by: Ryan Sutherland, et al.
Published: (2024)
Extended versus limited pelvic lymph node dissection and long‐term outcomes in high‐risk prostate cancer before radiotherapy
by: Georgios Daouacher, et al.
Published: (2026)
by: Georgios Daouacher, et al.
Published: (2026)
PARP inhibitor‐based treatment in metastatic, castration‐resistant prostate cancer (mCRPC): A systematic review and meta‐analysis
by: Michela Roberto, et al.
Published: (2025)
by: Michela Roberto, et al.
Published: (2025)
The significant costs of prostate cancer management—An analysis from a Caribbean hospital
by: Geneva Pantoja, et al.
Published: (2025)
by: Geneva Pantoja, et al.
Published: (2025)
Impact of recreational football in men with prostate cancer undergoing androgen deprivation therapy
by: Sofia Mesquita, et al.
Published: (2025)
by: Sofia Mesquita, et al.
Published: (2025)
Targeted Prostate Health Checks, a novel system to identify men with prostate cancer—A pilot study
by: Stephen Langley, et al.
Published: (2024)
by: Stephen Langley, et al.
Published: (2024)
The carbon footprint of transperineal prostate biopsy
by: Daniel A. Carson, et al.
Published: (2025)
by: Daniel A. Carson, et al.
Published: (2025)
Does bladder outflow obstruction obfuscate the traditional clinical factors that are used to assess the risk of prostate cancer at rapid‐access diagnostic clinics?
by: Thomas Philip Cahill, et al.
Published: (2024)
by: Thomas Philip Cahill, et al.
Published: (2024)
Real‐world clinical outcomes of oligometastatic prostate cancer using SBRT: An Australian experience
by: Samantha Shekar, et al.
Published: (2025)
by: Samantha Shekar, et al.
Published: (2025)
Analysis of urinary volatile organic compounds for prostate cancer diagnosis: A systematic review
by: Jonathon Dawson, et al.
Published: (2024)
by: Jonathon Dawson, et al.
Published: (2024)
A machine learning algorithm for automatic tumour board recommendations in prostate cancer patients
by: Marcus Sondermann, et al.
Published: (2025)
by: Marcus Sondermann, et al.
Published: (2025)
Sociodemographic landscape of suspected prostate cancer referrals and diagnoses across North East London
by: Muhammad Haider, et al.
Published: (2025)
by: Muhammad Haider, et al.
Published: (2025)
AI‐enhanced micro‐ultrasound improves detection of clinically significant prostate cancer at biopsy
by: Muhammad Imran, et al.
Published: (2026)
by: Muhammad Imran, et al.
Published: (2026)
Effect of prior HoLEP procedure on multiparametric MRI accuracy in detection of prostate cancer
by: Austin Drysch, et al.
Published: (2025)
by: Austin Drysch, et al.
Published: (2025)
MRI performance to identify clinically significant prostate cancer following focal cryo‐ablation
by: Herbert Lepor, et al.
Published: (2025)
by: Herbert Lepor, et al.
Published: (2025)
A pilot study evaluating the safety and efficacy of En‐bloc holmium laser enucleation of the prostate in patients with a history of radiation therapy or high intensity focused ultrasound for management of organ confined prostate cancer with review of the literature
by: Renil S. Titus, et al.
Published: (2025)
by: Renil S. Titus, et al.
Published: (2025)
Long non‐coding RNAs define favourable biology in high‐risk non‐muscle‐invasive bladder cancer
by: Rachel Weng, et al.
Published: (2025)
by: Rachel Weng, et al.
Published: (2025)
Similar Items
-
PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer
by: Nicole Handa, et al.
Published: (2025) -
First validation of the Prostatype® P‐score in an Asian cohort: Improving risk stratification for prostate cancer
by: See‐Tong Pang, et al.
Published: (2025) -
Oncological outcomes post focal low‐dose‐rate brachytherapy in low‐intermediate risk prostate cancer
by: Mohammadmehdi Adhami, et al.
Published: (2026) -
Variation in harms and benefits of prostate‐specific antigen screening for prostate cancer by socio‐clinical risk factors: A rapid review
by: Abel Tesfai, et al.
Published: (2024) -
Comparing outcomes of Aquablation versus holmium laser enucleation of prostate in the treatment of benign prostatic hyperplasia: A network meta‐analysis
by: Ansh Bhatia, et al.
Published: (2024)